Yvonnda West for their important contribution to data collection and data analyses
Calcif Tissue Int 81 (2): 99-106 (2007) For more Drug Warnings (Complete) data for L-CARNITINE (9 total), please visit the HSDB record page
They should not be used by: People with a history of pancreatitis (inflammation of the pancreas) Anyone with a personal or family history of medullary thyroid cancer (a rare type of thyroid cancer) People with multiple endocrine neoplasia type 2 (MEN 2, a rare inherited condition that raises the risk of certain hormone-related tumors, including thyroid cancer) Women who are pregnant or breastfeeding People with severe stomach or bowel problems, such as gastroparesis (slow stomach emptying that causes nausea, fullness, or vomiting) or inflammatory bowel disease (chronic inflammation of the digestive tract, such as Crohns disease or ulcerative colitis) Those with severe kidney problems, especially with certain types of GLP-1 medicines, such as exenatide Anyone with allergies to GLP-1 medications or who has had a severe reaction to them Use in children is limited to certain GLP-1 medicines approved for adolescents with obesity
this off-label use is not backed by the same level of controlled human trial evidence as the lipodystrophy indication Known risks and side effects: Injection site reactions, including erythema, pruritus, pain, and bruising at the injection site Arthralgia (joint pain) and peripheral edema (fluid retention), recognized class effects of GH-axis stimulation Increases in blood glucose and reduced insulin sensitivity, with clinical trials showing a higher rate of elevated HbA1c and new-onset hyperglycemia versus placebo Formation of anti-tesamorelin antibodies, reported in a substantial proportion of treated patients, with unclear long-term clinical significance Contraindicated in people with active malignancy, pituitary or hypothalamic disruption, or pregnancy, per FDA labeling Evidence snapshot: The strongest evidence is a set of Phase 3 human randomized controlled trials that supported FDA approval of tesamorelin for reducing visceral abdominal fat in HIV-associated lipodystrophy (approved 2010), plus a separate placebo-controlled human RCT (Baker et al., 2012, Archives of Neurology) showing improved executive function in older adults
Schedule a consultation today and take the next step toward feeling stronger, sharper, and more balanced
FAQ What is GLP-1 telehealth prescribing
